Repligen Corporation Stock News

Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.

Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

This is the second part of my update on the holdings in my portfolios. See whether my outlook has changed based on performance over the last few quarters.

Related Stocks: RGEN , DASH , NTLA , ABNB , MNDY , BIO , CRL , S , S , 0A8V , FRSH , FRSH , PINS , WIX , CSGP , NARI , ZEN , GH , 7974 , UBER , RNG , QTWO , 03690 , EQIX ,

Simon Quick Advisors LLC raised its position in Repligen Co. (NASDAQ:RGEN) by 68.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 128 shares of the biotechnology companys stock after buying an additional 52 shares during the quarter. Simon Quick []

QIAGEN (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Earnings & Valuation This table compares QIAGEN and Repligens revenue, earnings per share and valuation. Gross Revenue []

Protein A Resin Market Survival Strategies explore Economic Impact in International Industries Manufactures, Growth, Size, Share, Trends, Development Challenges and Opportunities till 2028. The new research on Protein A Resin gives a fundamental data and factually assessed information about the

Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.

Justine Dwyer Waterford is to receive a welcome jobs boost with the announcement that 250 new jobs are to be created in the city by an existing business – Infosys BPM. The business process management company is setting up a state-of-the-art delivery centre in Railway Square in the heart of the city to provide support services for several large global companies. The new positions will cover several functions across various job levels from customer and technical support to senior level positions in finance, HR, planning and capacity management. The company set up its Irish operation in 2014 in Dublin, delivering services across telecommunications, manufacturing, social media, healthcare, edtech and fintech sectors. Since then, Infosys BPM has further expanded in Ireland and the UK. The company has had a presence in Waterford since its acquisition of Eishtec in 2019. New office at Railway Square. Fine Gael Senator John Cummins welcomed the news saying it was fantastic to see another IDA jobs announcement for Waterford following similar recent announcements by Bausch and Lomb, Repligen, Horizon Therapeutics and Tegus. “This latest announcement brings to 660, the number of IDA backed jobs that have been created in the past five months,” he said.

Sector ETF report for PBE

New Jersey, United States,- Verified Market Research has recently published a research report titled, “Protein A Resin Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application”. Primary and secondary research methodologies have been used to

Kestra Private Wealth Services LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,736 shares of the biotechnology companys stock, valued at approximately $502,000. A number of other hedge []

Crossmark Global Holdings Inc. cut its stake in Repligen Co. (NASDAQ:RGEN) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,080 shares of the biotechnology companys stock after selling 380 shares during the quarter. Crossmark Global Holdings Inc.s holdings in Repligen []

Zacks Investment Research upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a strong-buy rating in a report issued on Tuesday, Zacks.com reports. Zacks Investment Research currently has $285.00 price target on the biotechnology companys stock. According to Zacks, Repligen''s third quarter-results beat estimates on both counts. The companys product franchises continue to witness []

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.